AbbVie Inc (ABBV) : Mizuho Trust Banking Ltd. reduced its stake in AbbVie Inc by 0.99% during the most recent quarter end. The investment management company now holds a total of 2,564,096 shares of AbbVie Inc which is valued at $170,691,871 after selling 25,623 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on Aug 2, 2016.AbbVie Inc makes up approximately 0.51% of Mizuho Trust Banking Ltd.’s portfolio.
Other Hedge Funds, Including , Nippon Life Insurance Co reduced its stake in ABBV by selling 3,325 shares or 1.01% in the most recent quarter. The Hedge Fund company now holds 324,494 shares of ABBV which is valued at $21,601,566. AbbVie Inc makes up approx 0.52% of Nippon Life Insurance Co’s portfolio.Chicago Equity Partners reduced its stake in ABBV by selling 265,955 shares or 97.42% in the most recent quarter. The Hedge Fund company now holds 7,030 shares of ABBV which is valued at $465,597. AbbVie Inc makes up approx 0.01% of Chicago Equity Partners’s portfolio.Concert Wealth Management boosted its stake in ABBV in the latest quarter, The investment management firm added 12,708 additional shares and now holds a total of 64,268 shares of AbbVie Inc which is valued at $4,256,470. AbbVie Inc makes up approx 0.56% of Concert Wealth Management’s portfolio.Hills Bank Trust Co boosted its stake in ABBV in the latest quarter, The investment management firm added 400 additional shares and now holds a total of 4,254 shares of AbbVie Inc which is valued at $269,746. AbbVie Inc makes up approx 0.10% of Hills Bank Trust Co’s portfolio. Keel Point added ABBV to its portfolio by purchasing 6,501 company shares during the most recent quarter which is valued at $421,070. AbbVie Inc makes up approx 0.18% of Keel Point’s portfolio.
AbbVie Inc closed down -0.2 points or -0.30% at $66.34 with 53,09,293 shares getting traded on Monday. Post opening the session at $66.38, the shares hit an intraday low of $65.75 and an intraday high of $66.67 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.